article

Design, formulation and manufacture of film-coated drug products

Posted: 25 October 2017 | | No comments yet

Film coating is a common step in tablet manufacture that can be used to improve product appearance, organoleptic properties, or to facilitate swallowing. Functional film coats can also be used as a part of the product’s stabilisation strategy and to modify or delay drug release.

Design

The film coat, along with the tablet shape and size, defines the appearance of the product. Distinctive colours and shapes can be important aspects of the brand image. Colour also helps patient to distinguish between different medications and is an important aspect of compliance. Patients are more responsive when the colour matches the therapeutic use, eg, blue is a calming colour and can be useful in sleep medications.1 Tablet colour is also linked with flavour perceptions2 – pink is considered to be sweeter than red, whereas, yellow is viewed as salty irrespective of the actual components of the formulation.3

Many elderly patients struggle to swallow solid oral dosage forms – a condition called dysphagia. Swallowing can be facilitated by both tablet design (small, caplet shaped) and the presence of a film coat.4 The US FDA has indicated that the absence of a film coat can either decrease or constrain tablet mobility compared with a coated tablet of the same size and shape.5

APIs are typically bitter tasting, and this can be a significant challenge in the development of oral liquid or oral suspension products, particularly for paediatric patients. For oral swallow tablets, this is less of an issue and it can be addressed using a simple aqueous film coat.6 The coat acts as a physical barrier between the buccal cavity and the API and the dosage form is typically swallowed whole, which minimises the opportunity for the solubilised drug to be present in the mouth. However, for dosage forms that are not swallowed whole, eg, chewable tablets, more bespoke film coating approaches may be required, which can include coating the granules as well as the tablet cores.6 The key design intent is to retard dissolution in the buccal cavity without affecting rapid dissolution in the stomach, ie, to not affect bioavailability.

Ibuprofen can be coated with methacrylic acid copolymer (Eudragit) to form microcapsules, which can be used to form chewable taste‐masked granules.7 Dimenhydrinate can be coated with Eudragit, starch or carboxymethyl cellulose polymers.8 A chewable paracetamol tablet has also been prepared by compressing coated granules. The API is coated with a mixture of cellulose acetate, cellulose acetate butyrate and hydroxypropyl cellulose,9 or with cellulose acetate, Eudragit E100 and polyvinyl pyrollidone.10

Functional film coatings

Stabilisation strategy

While pack design, including the use of desiccants, is the principal strategy for stabilising drugs prone to hydrolysis,11 specialised moisture protective film coatings, eg, Opadry II, Opadry AMB, etc, can provide additional moisture protection. This is particularly appropriate for the protection of the bulk product prior to packaging or during transit if the packaging is performed at a remote facility.

A recent publication highlighted that moisture protection barriers could stabilise a moisture-sensitive API while also reducing potential incompatibilities with a second API in a fixed-dose combination (FDC) tablet. A drug layered pellet containing a moisture sensitive DPP-IV inhibitor was coated with various different seal coats and moisture barriers. Compression aids were added together with granulated metformin hydrochloride and the blend was compressed into a FDC tablet.12 A slightly different approach was also developed for a FDC anti-malarial tablet of artesunate and amodiaquine. The main issue was the hydrolytic instability of artesunate, particularly in the presence of amodiaquine. This was addressed by basifying the dry granulation blend using calcium carbonate before the two layers were compressed into a bi-layer tablet and film coated with a moisture barrier coat.13

Obviously, aqueous film coating processes can still present significant challenges to moisture-labile APIs. This can be addressed using solvent film coating.13,14 However, the product must be manufactured in an explosion-proof facility and the product will need to comply with current residual solvent guidelines (ICH Q3C (R6)).15 Titanium dioxide is often used as an inert pigment for enhancing film opacity for photo-labile drugs, eg, nifedipine. Films with contrast ratios values of >98% gave good light protection and this could be achieved using a coating suspension containing 29.5% titanium dioxide with a film thickness of 145µm.16

Delayed release

Classically, enteric coating with pH-sensitive polymeric coats has been used to delay the release of certain medicinal products. This is either to protect the product against the acidic environment in the stomach, eg, proton pump inhibitors or to protect the stomach against gastric bleeding from the routine use of non-steroidal anti-inflammatory drugs like aspirin. As such, acid-resistant polymers, eg, Eudragit L, Kollicoat D and Kollicoat DP, have been commonly used to prevent release at pH 1.2, with enhanced solubility at pH over 5.5, thereby bypassing the stomach and releasing the drug in the small intestine. Some delayed-release products, eg, 5-aminosalicylic acid (5-ASA), are systemically toxic and are used for topical treatment in the colon for irritable bowel disease. In these cases, the design intent is to delay the release until the colon and this is achieved by polymers that release at above pH 7 using Eudragit S, Eudragit FS and other suitable polymers.

Some products use both approaches, with the first layer dissolving in the small intestine (> pH 5.5) releasing part of the product, and the second coat dissolving in the colon (> pH 7). This can be achieved using either layer coating17 or the preparation of two different coated granules. An example of the latter approach was described by Howden.18 The product was comprised of two PPI granules: the first component released one to two hours after dosing and provided day-time treatment for gastroesophageal reflux disease (GORD); the second component released about five to six hours after dosing and addressed breakthrough GORD often seen in the late evening or overnight.

Based on the variable gastrointestinal pH observed within the general population (and especially with colonic-pH), the effectiveness of colon-targeting using pH alone (pH > 7) has been widely questioned.19 Several alternative strategies have been proposed. Resistant starch or high-amylose maize starch can be blended with Eudragit S polymer to facilitate reproducible colonic-release. This approach relies both on colonic-pH and selective microbial degradation of the starch in the colon.20 This approach demonstrated consistent release at the ileocecal junction (ICJ) or within the colon, irrespective of dietary conditions.19 A layer-coating approach utilising an outer layer of Eudragit S and an inner alkaline buffered layer was also developed. This ensured that the inner alkaline layer (pH > 7) promoted the dissolution of the polymer permitting targeted release at the ICJ. This concept was demonstrated using scintigraphy in human volunteer studies.21,22 Disintegrants can also be added to the Eudragit S layer to facilitate targeted release. Studies in fasted human volunteers showed reproducible release in the caecum and colon using this approach.23,24

Modified release

Modified-release (MR) dosage forms can be simplistically divided into two main types: either matrix tablets or multiparticulates, where the release-controlling polymer is added as a pH-sensitive film coat.25 Drug dose in a multiparticulate delivery system is divided across the whole system; therefore failure of a few units will be significantly less severe than the failure of a single-unit matrix tablet system, ie, dose dumping.

Multiparticulates typically comprise inert spherical particles, ie, nonpareil seeds layer-coated with drug and various functional and non-functional film seal coats. This approach can be used to achieve MR release profiles, delayed and/or targeted release, and/or pulsatile release. A recent review summarised the various different multiparticulate approaches, eg, swelling/rupturing, dissolution and/or erosion, and modification of the intrinsic permeability of the film coat.26 Many different polymers have been evaluated as coatings for multiparticulate systems; some of these include Eudragit RS/RL,27 starch acetate,28 ethyl cellulose29 and Eudragit S.30 In addition, aqueous or organic film coating can influence the performance of the polymer and the release profile of the resultant product.31

Pulsatile delivery could be achieved by layering of nonpareil cores with an active layer, a swelling layer comprising a binder and superdisintegrant, eg, Ac-Di-Sol, sodium starch glycolate, and an insoluble, water-permeable polymeric coat, eg, ethyl cellulose.32 Similarly, the permeability of ethyl cellulose coats (and thereby the release profiles) could be easily modified in a pH-independent fashion by adding varying levels of polyvinyl alcohol/polyethylene glycol.29

Several quality by design (QbD) approaches to the optimisation of different types of polymeric film coats have been published.27,28 The former statistically assessed three critical processing parameters (CPP), ie, plasticiser concentration, polymer ratios (Eudragit RS/RL) and coat weight. The optimised formulation delivered a release profile in line with predictions.27 Similarly, three comparable CPPs, ie, curing temperature, plasticiser concentration and coat weight, were assessed in the latter case. The drug release profiles were again aligned with model predictions.28

Dose dumping

Many modified-release (and some delayed-release) products contain higher levels of active than the corresponding instant-release product. Therefore, dose dumping is a major risk for these dosage forms. That is, the potential for the drug to be released instantaneously, rather than in a controlled fashion over several hours. The situation is most concerning for drugs with narrow therapeutic windows, eg, theophylline. Dose dumping has also been reported to occur in the presence of alcohol. FDA requested the withdrawal of once-daily hydromorphone as a result of alcohol-induced dose dumping.33 Some polymeric excipients, eg, Eudragit, are more soluble in the presence of alcohol and this affects their ability to retard release of the drug and leads to dose dumping. For other excipients, eg, hydroxypropyl methylcellulose (HPMC), alcohol retards swelling of the tablet matrix and inhibits the release-controlling mechanisms.34,35

There are now requirements to perform in vitro dissolution testing in hydro-alcoholic media for both modified- and delayed-release products.36 Since Eudragit-based polymers are heavily used in functional coats there is obviously a risk associated with these types of product. Three mesalazine (5-ASA) delayed-release/extended-release products were tested for dose dumping in the presence of hydroalcoholic media. The two delayed-release products were enteric coated, whereas the extended-release product used an ethyl cellulose matrix tablet approach. Alcohol compromised the integrity of the enteric coat during the acid stage of the test and the drug was released much earlier than intended (distal end of small intestine/colon).37,38 Similarly, alcohol affected the release rate from the ethyl cellulose extended-release product.38

A significant number of patients are now prescribed proton pump inhibitors that typically increase gastric pH to values greater than 4.0 (cf, pH 1.2 in the ‘normal’ population).39 This can potentially have a significant effect on enteric coats, which are designed to be insoluble at pH 1.2 and to solubilise at pH > 5.5.40

Conclusions

Film coating is commonly used in tablet development to address certain universal challenges. Dysphagia, poor palatability and brand image can all be addressed using non-functional film coats. Stability can often be improved by the judicious selection of a film coat with decreased moisture permeability. pH-sensitive film coats are typically used to delay or modify drug release to facilitate improved patient outcomes. However, the high pH variability seen in typical patient populations, often exacerbated by co-medications such as PPIs that increase gastric pH to over 4.0, can compromise the clinical utility and safety of these pH-sensitive film coats. This can be addressed by modifying the permeability of these film coats with additives such as superdisintegrants, basifiers, or microbial sensitive excipients.  

BIOGRAPHY

Dave Elder has nearly 40 years of service within the pharmaceutical industry at Sterling, Syntext and GlaxoSmithKline. He is now an independent GMC consultant. Dr Elder is a visiting professor at King’s College, London, and is a member of the British Pharmacopoeia. He is a member of the Joint Pharmaceutical Analysis Group (JPAG), and a member of the Analytical Division Council of the Royal Society of Chemistry.

To view references visit europeanpharmaceuticalreview.com/5-17-Elder

References

  1. Color Matters: The color of medications. https://www.colormatters.com/color-symbolism/the-color-of-medications. Accessed on 09 September 2017.
  2. Delwiche J. The impact of perceptual interactions on perceived flavor. Food Qual. Prefer. 2004;15:137–146.
  3. Srivastava RK, More AT. Some aesthetic considerations for over the‐counter (OTC) pharmaceutical products. Int J Biotechnol. 2010;11:267-283.
  4. Liu F, Ranmal SL, Batchelor HK, Orlu-Gul M, Ernest TB, Thomas IW, Flanagan T, Tuleu C. Patient-Centred Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations. Drugs. 2014;74;1871-1889.
  5. FDA. 2015. Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules. Guidance for Industry. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER) June 2015.
  6. Sohi H, Sultana Y, Khar RK. Taste Masking Technologies in Oral Pharmaceuticals: Recent Developments and Approaches. Drug Dev Ind Pharm. 2004;30(5):429-448.
  7. Shen RW. Taste Masking of Ibuprofen by Fluid Bed Coating. US Patent 5,552,152, September 3, 1996.
  8. Gergely G, Gergely T, Gergely I. Pharmaceutical Preparation in the Form of an Effervescent and/or Disintegrating Tablet or an Instant Granule and Process of Producing It. PCT Int Appl. WO9313760, July 22, 1993.
  9. Roche EJ. Taste‐Masking and Sustained‐Release Coatings for Pharmaceuticals. Eur Pat Appl. EP0459695, December 4, 1991.
  10. Hoy MR, Roche EJ. Taste Mask Coating for Preparation of Chewable Pharmaceutical Tablets. Eur Pat Appl. EP0523847, January 20, 1993.
  11. Waterman KC, MacDonald BC. Package selection for moisture protection for solid, oral drug products. J Pharm Sci. 2010; 99:4437-4452.
  12. Burke MD, He X, Cook C, Petrov GA, Long S, Coffin MD. Stability Enhancement of Drug Layered Pellets in a Fixed Dose Combination Tablet. AAPS PharmSciTech. 2013;14(1):312-320.
  13. Modi FP, Patel PR. Formulation, optimization and evaluation of fixed dose combination moisture barrier film coated bilayer tablet of artesunate and amidaquine hydrochloride. Int J PharmTech Res. 2011;3(4):2124-2134.
  14. Parmar DK, Bhatt MN, Pathak LN, Patel DL, Kela NA, Nathani SH, Chauhan VV. An overview: Aqueous film coating technology on tablets. Int J Pharm Chem Sci. 2012;1(3):994-1001.
  15. ICH Q3C(R6). Impurities: Guidelines for residual solvents. Current step 4 version, dated October 20, 2016.
  16. Béchard SR, Quraishi O, Kwong E. Film coating: Effect of titanium dioxide concentration and film thickness on the photostability of nifedipine. Int J Pharm. 1992;87:133-139.
  17. Park HJ, Jung HJ, Ho MJ, Lee DR, Cho HR, Choi YS, Jun J, Son M, Kang MJ. Colon-targeted delivery of solubilized bisacodyl by doubly enteric coated multiple-unit tablet. Eur J Pharm Sci. 2017;102:172-179.
  18. Howden CW. Update on dual delayed-release PPI formulations. Gastroenterology Hepatology. 2010;6(7):417-419.
  19. Maroni A, Moutaharrik S, Zema L, Gazzaniga A. Enteric coatings for colonic drug delivery: State of the art. Exp Opin Drug Deliv. 2017;14:1027-1029.
  20. Ibeke VC, Khela MK, Evans DF. A new concept in colonic drug targeting: A combined pH-responsive and bacterially-triggered drug delivery technology. Aliment Pharmacol Ther. 2008;28:911-916.
  21. Liu F, Moreno P, Basit AW. A novel double-coating approach for improved pH-triggered delivery to the ileo-colonic region of the gastrointestinal tract. Eur J Pharm Biopharm. 2010;74:311-315.
  22. Varum FJO, Hatton GB, Freire AC, Basit AW. A novel coating concept for ileo-colonic drug targeting: Proof of concept in humans using scintigraphy. Eur J Pharm Biopharm. 2013;84:573-577.
  23. Schellekens RCA, Stellaard F, Mitrovic D, Suurman FE, Kosterink JG, Frijlink HW. Pulsatile drug delivery to the ileo-colonic segments by structured incorporation of disintegrants in pH-responsive polymer coatings. J Control Rel. 2008;132:91-98.
  24. Schellekens RCA, Stellaard F, Olsder GG, Woerdenbag HJ, Frijlink HW, Kosterink JG. Oral ileocolonic drug delivery by the colopulse-system: a bioavailability study in healthy volunteers. J Control Rel. 2010;146:334-340.
  25. Tang ESK, Chan LW, Heng PWS. Coating of multiparticulates for sustained release. Am J Drug Deliv. 2005;3(1):17-28.
  26. Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery: Current perspectives. J Control Rel. 2009;134:74-80.
  27. Kramar A, Turk S, Vrecer F. Statistical optimisation of diclofenac sustained release pellets coated with polymethacrylic films. Int J Pharm. 2003;256:43-52.
  28. Nutan MTH, Soliman MS, Taha EI, Khan MA. Optimization and characterization of controlled release multi-particulate beads coated with sodium acetate. Int J Pharm. 2005;294:89-101.
  29. Siepmann F, Hoffmann A, Leclercq B, Carlin B, Siepmann J. How to adjust the desired drug release patterns from ethylcellulose-coated dosage forms. J Control Rel. 2007;119:182-189.
  30. Lotikar V, Keddar U, Shidhaye S, Kadam V. pH-responsive dual pulse microparticulate dosage form for the treatment of rheumatoid arthritis. Drug Dev Ind Pharm. 2010;36:1295-1302.
  31. Lecomte F, Siepmann J, Walther M, MacRae RJ, Bodmeier R. Polymer blends used for the coating of multiparticulates: Comparison of aqueous and organic coating techniques. Pharm Res. 2004;21:882-890.
  32. Mohamad A, Dashevsky A. Development of a pulsatile multiparticulate drug delivery system coated with aqueous dispersion Aquacoat ECD. Int J Pharm. 2006;318:124-131.
  33. Walden M, Nicholls FA, Smith KJ. The effect of ethanol on the release of opioids from oral prolonged-release preparations. Drug Dev Ind Pharm. 2007;33(10):1101-1111.
  34. Levina M, Vuong H, Rajabi-Siahboomi AR. The influence of hydro-alcoholic media on hypromellose matrix systems. Drug Dev Ind Pharm. 2007;33:1125–1134.
  35. Avachat AM, Nandare DS. Effects of alcohol on drug release kinetics from HPMC-based matrix tablets using model drugs. Dissol Technol. 2014;11-17.
  36. Friebe TP, Aszgarzadeh F, Gray A, Hughes K, Hebestreit J-P, Rosiaux Y, Yunis M, Faham A. Regulatory considerations for alcohol-induced dose dumping of oral modified-release formulations. Pharm Technol. 2015;38(10):40-46.
  37. Fadda HM, Mohamed MAM, Basit AW. Impairment of the in vitro drug release behaviour of oral modified release preparations in the presence of alcohol. Int J Pharm. 2008;360:171–176.
  38. D’Souza S, Mayock S, Salt A. A review of in vivo and in vitro aspects of alcohol induced dose dumping. AAPS Open. 2017 https://aapsopen.springeropen.com/articles/10.1186/s41120-017-0014-9. Accessed on 09 September 2017.
  39. Miner P, Katz PO, Chen Y, Sostek M. 2003. Gastric Acid Control With Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, and Rabeprazole: A Five-Way Crossover Study. Am J Gastro. 2003;98(12):2616-2620.
  40. Thakral S, Thakral NK, Majumdar DK. Eudragit: a technology evaluation, Expert Opin Drug Deliv. 2013;10(1):131-149.

Related topics

Related organisations

Related people

Send this to a friend